Half-year report · HY
7733.TEDINET S100WYDD
Period2025-04-01 → 2025-09-30
Filed2025-11-07
StandardIFRS
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥454.4bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥997.3bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥474.0bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥46.1bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥70.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥44.8bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥159.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥68.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥29.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥117.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥49.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥29.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥49.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.38T | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.43T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.37T | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥651.2bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥681.5bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥733.6bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥751.7bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥703.1bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥757.2bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥733.6bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥751.7bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥703.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥147.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥252.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥245.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥340.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥21.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥190.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥93.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥50.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥65.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥30.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥77.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥211.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥156.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥26 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥102.99 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥42.24 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥25.96 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥102.8 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥42.16 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 53.0% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 52.4% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 51.4% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | −¥41m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥3.1bn |
| Gastrointestinal Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥53.4bn |
| Surgical And Interventional Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥4.2bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥49.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥387m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥9.0bn |
| Gastrointestinal Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥77.6bn |
| Surgical And Interventional Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥79.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 639
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss before tax IFRS | InterimDuration | 44784000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | InterimDuration_jpcrp040300-ssr_E02272-000GastrointestinalSolutionsReportableSegmentMember | -4240000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | InterimDuration_jpcrp040300-ssr_E02272-000SurgicalAndInterventionalSolutionsReportableSegmentMember | 457000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | InterimDuration_ReportableSegmentsMember | -3783000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | InterimDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | InterimDuration | -3783000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_jpcrp040300-ssr_E02272-000GastrointestinalSolutionsReportableSegmentMember | 19340000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_jpcrp040300-ssr_E02272-000SurgicalAndInterventionalSolutionsReportableSegmentMember | 13076000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_ReportableSegmentsMember | 32416000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 29000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_ReconcilingItemsMember | 505000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration | 32950000000 | JPY |
| Impairment losses pl IFRS | InterimDuration_jpcrp040300-ssr_E02272-000GastrointestinalSolutionsReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | InterimDuration_jpcrp040300-ssr_E02272-000SurgicalAndInterventionalSolutionsReportableSegmentMember | 2130000000 | JPY |
| Impairment losses pl IFRS | InterimDuration_ReportableSegmentsMember | 2130000000 | JPY |
| Impairment losses pl IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Impairment losses pl IFRS | InterimDuration_ReconcilingItemsMember | 148000000 | JPY |
| Impairment losses pl IFRS | InterimDuration | 2278000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-07 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第158期(2026年３月期)中（自 2025年４月１日 至 2025年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)オリンパス株式会社 | |
| Company name in english cover page | FilingDateInstant | OLYMPUS CORPORATION | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)取締役 代表執行役 社長兼 CEO ボブ・ホワイト | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都八王子市石川町2951番地 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)042-642-2111(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)経理部門バイスプレジデント 青柳 隆之 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都八王子市石川町2951番地 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)042-642-2111(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)IR部門バイスプレジデント 櫻井 隆明 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E02272 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 77330 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)オリンパス株式会社 | |
| Filer name in english | FilingDateInstant | OLYMPUS CORPORATION | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2025-04-01 | |
| Current period end date | FilingDateInstant | 2025-09-30 | |
| Type of current period | FilingDateInstant | HY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |